Search Results
Your search for ,New matches 16912 pages
Showing 10401 - 10450Palliative Care Consultations for Patients With Advanced Cancers May Reduce Hospitalization and Improve Quality of Care
Patients admitted to the hospital with advanced cancers who were referred early to palliative care had decreased health-care utilization and increased use of support services following discharge, according to a new study led by researchers at the Icahn School of Medicine at Mount Sinai. Published...
FDA Approves Maintenance Niraparib for Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, whose tumors have achieved complete or partial response to platinum-based chemotherapy....
ASCO and Cancer Care Ontario Update Guideline on Radiation Therapy for Prostate Cancer
The American Society of Clinical Oncology (ASCO) and Cancer Care Ontario today issued a joint clinical practice guideline update on brachytherapy for patients with prostate cancer. The update provides evidence-based recommendations for different patient risk groups and specifies the most effective...
New Study Finds Most Cancer Mutations Due to Random DNA-Copying Errors
Johns Hopkins Kimmel Cancer Center scientists report data from a new study providing evidence that random, unpredictable DNA copying “mistakes” account for nearly two-thirds of the mutations that cause cancer. Their research is grounded on a novel mathematic model based on DNA...
Guidelines Planned on Management of Immunotherapy Side Effects: ASCO and NCCN to Collaborate on Development
Given the pace of advances in immunotherapy in recent years and physicians’ need to keep up with these developments, ASCO and the National Comprehensive Cancer Network® (NCCN®) have announced a joint collaboration to publish practical clinical guidance on the management of side effects caused by...
An Evening for Cancer Survivors and Caregivers: Bringing Together a Community of Support
On January 26, 2017—prior to the official opening of the 2nd Annual Cancer Survivorship Symposium—cancer survivors, caregivers, patient advocates, family physicians, oncology providers, and others gathered in San Diego, California, to make connections, discuss survivorship issues, and get expert...
New ASCO Answers Fact Sheets on MDS, Bone Marrow Transplant for Your Practice
Be sure to check out new ASCO Answers fact sheets on myelodysplastic syndrome (MDS) and understanding bone marrow transplantation at Cancer.Net. These 1-page (front and back) introductions include an overview, illustrations, terms to know, and questions to ask the doctor. Find these and a library...
ASCO Launches Its New Journal Dedicated to Informatics
On February 23, 2017, ASCO launched its newest online-only journal, JCO Clinical Cancer Informatics (JCO CCI). The first four articles published in JCO CCI are: 1) An editorial from JCO CCI Editor-in-Chief Debra A. Patt, MD, MPH, MBA, introducing the publication and laying out its objective of...
Mammography-Detected Small Breast Cancers May Represent Overdiagnosis, With Declining Mortality Reflecting Improved Systemic Therapy
In a study using Surveillance, Epidemiology, and End Results (SEER) data reported in The New England Journal of Medicine, H. Gilbert Welch, MD, of Dartmouth Institute for Health Policy and Clinical Practice, and colleagues found that screening mammography has resulted in a substantial increase in...
New Supportive Care Resources From NCCN Help Patients With Cancer Confront Distress
All patients with cancer experience some level of distress associated with their cancer diagnosis and the effects of the disease and its treatment—regardless of the stage of disease. Not only does distress affect a patient’s mental and psychosocial well-being, but because distress is a...
Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines 126
Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discusses molecular abnormalities and their use in the diagnosis, risk stratification, and selection of treatment for myelofibrosis.
FDA Approves Avelumab for Metastatic Merkel Cell Carcinoma
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to avelumab (Bavencio) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma, including those who have not received prior chemotherapy. Avelumab is a programmed cell...
Anne Friedman Glauber, Cofounder of Online Pancreatic Cancer Forum, Dies at Age 63
Anne Friedman Glauber, 63, co-founder of Let’s Win, an online community for persons affected by pancreatic cancer, recently passed away at her home in New York City, after a courageous battle with the disease. Ms. Glauber’s dedication to the organization (www.letswinpc.org) helped countless...
Financial Burden of Targeted Oral Therapy for Patients With Chronic Myeloid Leukemia
In a study reported in the Journal of Oncology Practice, Chan Shen, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues found that more than three-quarters of patients receiving targeted oral therapy for chronic myeloid leukemia (CML) reached the catastrophic phase of the...
Reducing Debilitating Symptoms of Advanced Colorectal Cancer
In a phase III trial reported in The Lancet Oncology, Tamas Hickish, MD, of Poole Hospital NHS Foundation Trust, Dorset, England, and colleagues found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite ...
Fox Chase Junior Investigators Win Awards for Pilot Projects
Fox Chase Cancer Center is pleased to announce the results of its American Cancer Society Institutional Research Grant Pilot Project Competition for Junior Investigators. The competition was open to eligible junior faculty at Fox Chase and Temple University Hospital. The awardees are Yibin Yang, ...
Discrimination in Medical Education—Another Perspective
I read with great interest Dr. Robert E. Montenegro’s comments in the The ASCO Post, January 25, 2017, where he felt “marginalized” when questioned about his country of origin or the quality of his English. As physicians, we constantly deal in a world of uncertainties and are required to address...
Arti Hurria, MD, Named Vice Provost at City of Hope
Geriatrician-oncologist Arti Hurria, MD, has been named Vice Provost for Clinical Faculty at City of Hope. “I spent most of my formative years at City of Hope and was very fortunate,” said Dr. Hurria, who’s been at the medical center for 10 years. “I had mentors who helped me along the way and...
Chief Clinical Officer’s Distinguished Chair Created at City of Hope to Honor Alexandra M. Levine, MD, MACP
A significant philanthropic gift from the Campbell family of Las Vegas, Nevada, will establish a new endowed Chair to honor City of Hope’s former Chief Medical Officer Alexandra M. Levine, MD, MACP. The recipient of the Deana and Steve Campbell Chief Clinical Officer’s Distinguished Chair, to be...
Acupuncture for the Management of Hot Flashes
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, present a case study...
Implications of SWOG S0777 and the Future of Combination Treatments for Multiple Myeloma
The treatment of multiple myeloma is becoming increasingly complicated. This is not only because of the complexity of the disease, but also because of the increasing number of effective combination treatments and continuous development of new drugs. This has resulted in an ever-increasing number ...
New First-Line Options for ALK-Positive Lung Cancer on the Horizon
Anaplastic lymphoma kinase (ALK) rearrangements define a subset of non–small cell lung cancer (NSCLC) patients for whom ALK inhibitors are highly effective. In PROFILE 1014, the multitargeted ALK inhibitor crizotinib (Xalkori) was shown to be superior to platinum/pemetrexed (Alimta) chemotherapy...
Markedly Improved Progression-Free Survival With First-Line Ceritinib vs Platinum Chemotherapy in ALK-Rearranged NSCLC
In the phase III ASCEND-4 trial reported in The Lancet, Jean-Charles Soria, MD, of Institut Gustave Roussy, and colleagues found that ceritinib (Zykadia) improved progression-free survival vs platinum-based chemotherapy in the first-line treatment of advanced anaplastic lymphoma kinase...
SSO 2017: Preclinical Trial Shows Intratumoral Vaccination Induces Antitumor Response in Pancreatic Cancer
Building on their previous research focusing on intratumoral vaccination for the most common form of pancreatic cancer, investigators from Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School have shown that in a mouse model of early-stage resected pancreatic...
ASCO Addresses New Policies That Threaten Access to Opioids
Since the mid-2000s, medication and illicit drug abuse in the United Sates has steadily increased, creating what has now been termed an “opioid epidemic.” In response, Congress and the Bush and Obama Administrations have launched intervention and regulatory proposals to help turn the troubling...
Benjamin Levy, MD, to Lead Medical Oncology at Sibley Memorial
Lung cancer specialist Benjamin Levy, MD, has been named the new Clinical Director of Medical Oncology and Medical Director of Thoracic Oncology for the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital in northwest Washington, DC. Dr. Levy is Former Director of Thoracic Medical...
Breast Surgeon Sheldon M. Feldman, MD, Joins Montefiore and Einstein Cancer Centers
Sheldon M. Feldman, MD, has been named Chief of the Division of Breast Surgery and Surgical Oncology and Director of Breast Cancer Services at Montefiore Einstein Center for Cancer Care, the clinical arm of the National Cancer Institute–designated Albert Einstein Cancer Center. He will also join...
Expert Point of View: Shridar Ganesan, MD, PhD
Shridar Ganesan, MD, PhD, of Rutgers Cancer Institute of New Jersey, discussed the study by Cristescu et al at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium. He noted that data from many sources have shown that point mutation burden correlates with response rate to checkpoint blockade....
Expert Point of View: Joseph Greer, PhD
“These data are consistent with other studies we have conducted in advanced lung cancer, in which we similarly found that one-third of patients believed that their metastatic lung cancer was curable. These patients ostensibly already had conversations with their oncologists about their prognosis...
Aligning Patient Expectations With Treatment Goals in the Metastatic Setting
More than one-third of men with incurable metastatic prostate cancer mistakenly believe that their cancer may be curable, according to a survey of patient expectations at an academic cancer center. “This study is part of a larger survey of treatment decision-making among men with metastatic...
Leukemia & Lymphoma Society Appoints Gwen Nichols, MD, as Chief Medical Officer
Leukemia & Lymphoma Society (LLS) has announced Gwen Nichols, MD, as its new Chief Medical Officer. A physician and scientific researcher, Dr. Nichols has dedicated her career to advancing cures for cancers through a unique combination of clinical, academic, and pharmaceutical experience. She...
Developing Better Multidisciplinary Strategies
“More than any other disease, head and neck cancer requires constant interplay between a number of different specialties,” Sandeep Samant, MD, Chief, Head and Neck Surgery, Northwestern Medicine, and Chair of the Multidisciplinary Head & Neck Symposium sponsored by the Robert H. Lurie...
IASLC Endorses Tobacco Reform Report Outlining Progress Toward Ending Adult Cigarette Smoking
The International Association for the Study of Lung Cancer (IASLC) has endorsed a report released by the Core Team for Tobacco Control that outlines key action items that can be taken immediately to accelerate progress toward ending cigarette smoking in adults. Issuing their Executive Summary ...
Expert Point of View: Ann H. Partridge MD, MPH
Ann H. Partridge MD, MPH, Director of Adult Cancer Survivorship Program at the Dana-Farber Cancer Institute, praised the “tremendous work” of Dr. Paskett and her colleagues but referred to the findings as “disappointing to say the least.”1 “Developing interventions to prevent or treat lymphedema...
Early PET Imaging May Guide Treatment Decisions in Esophageal Cancer
In patients with resectable esophageal or gastroesophageal junction cancer, positron-emission tomography (PET) imaging was used to assess response to induction chemotherapy. PET nonresponders were identified after the first few cycles and were switched to an alternate regimen. This strategy greatly ...
Nivolumab Shows Benefit in Advanced Hepatocellular Carcinoma
In patients with advanced hepatocellular carcinoma, treatment with nivolumab (Opdivo) resulted in responses and long-term survival in patients who were either previously treated or naive to sorafenib (Nexavar), CheckMate 040 has shown.1 Altogether 19% of patients responded to the antibody...
New Antiviral Agent May Prevent Posttransplant Cytomegalovirus Infections
Patients receiving the antiviral letermovir (MK-8228, AIC246), as compared to placebo, were almost twice as likely to avoid infection with cytomegalovirus or fail for other reasons in a randomized phase III international trial presented at the 2017 BMT Tandem Meetings, the joint meeting of the...
The Path Forward for Clinical Pathways in Oncology
The year 2016 was a memorable one for oncology. In January, President Barack Obama announced the launch of the National Cancer Moonshot initiative, spearheaded by Vice President Joe Biden, which aims to accelerate cancer research. And in December, through bipartisan Congressional support, the 21st ...
Expert Point of View: Ann W. Silk, MD
Ann W. Silk, MD, of Rutgers Cancer Institute of New Jersey, New Brunswick, presented the day’s highlights and commented that the study by Hellmann et al shows the utility, and, in fact, the necessity, of developing a new means of estimating outcomes for patients treated with immunotherapies....
Pembrolizumab Affords Long-Term Survival to One-Fourth of Selected Patients With NSCLC, Alternative Statistical Model Suggests
Statistical modeling of long-term survival from the KEYNOTE trials of the programmed cell death protein 1 (PD-1)–inhibitor pembrolizumab (Keytruda) estimates that one-quarter of appropriately selected patients with advanced non–small cell lung cancer (NSCLC) may attain long-term survival.1 “In...
Multikinase Inhibitor Treatment Responses in Patients With RET-Rearranged NSCLC
In a report from the Global, Multicenter RET Registry in the Journal of Clinical Oncology, Gautschi et al documented response rates with multikinase RET inhibitors in patients with RET-rearranged non–small cell lung cancer (NSCLC). Study Details The study involved registry data (through...
Testosterone Replacement Therapy and Risk of Prostate Cancer
In a Swedish study reported in the Journal of Clinical Oncology, Loeb et al found that use of testosterone replacement therapy was not associated with an increased risk of prostate cancer and was associated with a lower risk of aggressive cancer among men developing the disease. Study Details The ...
Japanese Phase II Trial of Nivolumab in Previously Treated Advanced Esophageal Cancer
In a Japanese phase II trial reported in The Lancet Oncology, Kudo et al found that nivolumab (Opdivo) had activity in heavily pretreated patients with advanced esophageal squamous cell carcinoma. Study Details In the study, with enrollment between February and November 2014, 65 patients...
ASCO Releases Its State of Cancer Care in America: 2017 Report
In a press briefing today on Capitol Hill, ASCO presented its fourth annual State of Cancer Care in America: 2017 report, which found that although the cancer care delivery system in the United States is undergoing profound changes to better meet the needs of cancer survivors, persistent hurdles...
Dexamethasone Mouthwash in Preventing Everolimus-Related Stomatitis in Women With Breast Cancer
In the phase II SWISH study reported in The Lancet Oncology, Rugo et al found that use of a dexamethasone-based mouthwash may prevent everolimus-related stomatitis in postmenopausal women receiving everolimus (Afinitor) for hormone receptor–positive, HER2-negative metastatic breast cancer....
Thoracic 2017: Updated Data Confirm Benefits of Single-Fraction SBRT for NSCLC
New research led by a radiation oncologist at Roswell Park Cancer Institute indicates that less may be more when it comes to some forms of radiation therapy for cancer. In a presentation highlighted in a plenary session (Abstract 4) at the 2017 Multidisciplinary Thoracic Cancers Symposium in San...
Belgian Study Combines BRAF and MEK Inhibition in Advanced BRAF 600–Mutant Melanoma
In a Belgian two-center phase II trial reported in The Lancet Oncology, Schreuer et al found that rechallenge with the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) showed activity in patients with BRAF V600–mutant melanoma whose disease had progressed on...
Adding Temozolomide to Short-Course Radiotherapy in Older Patients With Glioblastoma
In a phase III trial reported in The New England Journal of Medicine, Perry et al found that adding temozolomide to short-course radiotherapy improved overall survival in patients aged ≥ 65 years with newly diagnosed glioblastoma. The survival advantage was largest among patients with methylated ...
Thoracic 2017: Combination of Radiation and Immune Checkpoint Therapy Holds Potential for Lung Cancer
An emerging approach for cancer treatment seeks to combine radiation therapy with immune checkpoint inhibitors to more effectively control tumors in the chest with an acceptable risk of severe treatment-related side effects. About 10% of patients in a retrospective analysis of metastatic lung...
Thoracic 2017: Proton Therapy Offers New Treatment Possibility for Recurrent Lung Cancer
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients ...
